Novo Nordisk: EVOKE Plus
What is the EVOKE Plus Study?
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
Participants will be randomized to either semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken.
Participants must have a study partner, who is willing to take part in the study.
More Information on Clinical Trials.gov